NCT00528177

Brief Summary

The purpose of this study is to determine whether oxycodone provides better analgesia compared to morphine after laparoscopic hysterectomy or myomectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Sep 2007

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

September 11, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 12, 2007

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2008

Completed
Last Updated

July 6, 2011

Status Verified

June 1, 2007

Enrollment Period

9 months

First QC Date

September 11, 2007

Last Update Submit

July 3, 2011

Conditions

Keywords

kappa-opioid receptormy-opioid receptoroxycodonemorphinepostoperative pain

Outcome Measures

Primary Outcomes (1)

  • Dosage relation between oxycodone and morphine. Pain score (VAS). Adverse effects.

    Within the first postoperative day (24 hours).

Study Arms (2)

O

ACTIVE COMPARATOR

This arm will receive intravenous oxycodone at the end of surgery and PCA oxycodone for postoperative pain relief.

Drug: Morphine and oxycodone

M

ACTIVE COMPARATOR

This arm will receive intravenous morphine at the end of surgery and PCA morphine for postoperative pain relief.

Drug: Morphine and oxycodone

Interventions

At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. The patients will use the PCA until the next morning.

MO

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients (American Society of Anaesthesiologists (ASA) I, II and III) due for elective, laparoscopic, non-malignant gynaecologic surgery: Hysterectomy or myomectomy.
  • Written informed consent.
  • Age: 18 to 70 years.

You may not qualify if:

  • Patients having used non-steroidal anti-inflammatory drugs (NSAIDs) the last 24 hours.
  • Sensitivity towards the study drugs.
  • Cardiovascular risk conditions: Heart failure, unstable hypertension, coronary artery disease.
  • Patients using opioids, steroids or anti-emetic drugs.
  • Serious mental disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ullevaal University Hospital

Oslo, Oslo County, 0407, Norway

Location

Related Publications (1)

  • Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg. 2009 Oct;109(4):1279-83. doi: 10.1213/ane.0b013e3181b0f0bb.

MeSH Terms

Conditions

MyomaPain, Postoperative

Interventions

MoxDuo

Condition Hierarchy (Ancestors)

Neoplasms, Muscle TissueNeoplasms, Connective and Soft TissueNeoplasms by Histologic TypeNeoplasmsPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Officials

  • Johan Ræder, Prof.MD,Phd

    Ullevaal University Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 11, 2007

First Posted

September 12, 2007

Study Start

September 1, 2007

Primary Completion

June 1, 2008

Study Completion

June 1, 2008

Last Updated

July 6, 2011

Record last verified: 2007-06

Locations